| UTHEALTH HOME ABOUT SBMI A-Z WEBMAIL INSIDE THE UNIVERSITY |
|
|||||||
|
Kinase Fusion Gene:CSNK1G3_HTN3 |
Kinase Fusion Protein Summary |
 Kinase Fusion gene summary |
| Kinase Fusion partner gene information | Kinase Fusion gene name: CSNK1G3_HTN3 | KinaseFusionDB ID: KFG1533 | FusionGDB2.0 ID: KFG1533 | Hgene | Tgene | Gene symbol | CSNK1G3 | HTN3 | Gene ID | 1456 | 3347 | |
| Gene name | casein kinase 1 gamma 3 | histatin 3 | ||||||||||
| Synonyms | CKI-gamma 3|CSNK1G3L | HIS2|HTN2|HTN5|Hst 3|PB | ||||||||||
| Cytomap | 5q23.2 | 4q13.3 | ||||||||||
| Type of gene | protein-coding | protein-coding | ||||||||||
| Description | casein kinase I isoform gamma-3casein kinase I | histatin-3basic histidine-rich proteinhistatin-4histatin-5histatin-6histatin-7histatin-8histatin-9histidine-rich protein 3 | ||||||||||
| Modification date | 20240305 | 20240305 | ||||||||||
| UniProtAcc | Q9Y6M4 | P15516 | ||||||||||
| Ensembl transtripts involved in fusion gene | ENST ids | ENST00000345990, ENST00000360683, ENST00000361991, ENST00000395411, ENST00000395412, ENST00000508708, ENST00000510842, ENST00000511130, ENST00000512718, ENST00000521364, | ENST00000381057, ENST00000526767, ENST00000530128, | |||||||||
| Context (manual curation of fusion genes in KinaseFusionDB) | PubMed: CSNK1G3 [Title/Abstract] AND HTN3 [Title/Abstract] AND fusion [Title/Abstract] | |||||||||||
| Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0) | CSNK1G3(122937737)-HTN3(70894176), # samples:1 | |||||||||||
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Tgene | HTN3 | GO:0090303 | positive regulation of wound healing | 18650243 |
| Kinase Fusion gene breakpoints across CSNK1G3 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Kinase Fusion gene breakpoints across HTN3 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Top |
Kinase Fusion Gene Sample Information |
| Kinase Fusion gene information. |
| Kinase Fusion gene information from four resources (ChiTars 5.0, ChimerDB 4.0, COSMIC, and CCLE) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Sample | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp |
| ChiTaRS5.0 | AK129614 | CSNK1G3 | chr5 | 122937737 | HTN3 | chr4 | 70894176 |
Top |
Kinase Fusion ORF Analysis |
| Kinase Fusion information from ORFfinder translation from full-length transcript sequence from KinaseFusionDB. |
| Henst | Tenst | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp | Seq length (transcript) | Seq length (amino acids) |
Top |
Kinase Fusion Amino Acid Sequences |
| For individual full-length fusion transcript sequence from KinaseFusionDB, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
| >Henst_Tenst_Hgene_Hchr_Hbp_Tgene_Tchr_Tbp_length(fusion AA)_AAseq |
Multiple Sequence Alignment of All Fusion Protein Isoforms |
Top |
Kinase Fusion Protein Functional Features |
| Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/:122937737/:70894176) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| CSNK1G3 | HTN3 |
| FUNCTION: Serine/threonine-protein kinase. Casein kinases are operationally defined by their preferential utilization of acidic proteins such as caseins as substrates. It can phosphorylate a large number of proteins. Participates in Wnt signaling. Regulates fast synaptic transmission mediated by glutamate (By similarity). {ECO:0000250}. | FUNCTION: Histatins are cationic and histidine-rich peptides mainly found in the saliva of higher primates (PubMed:3286634). They are considered to be major precursors of the protective proteinaceous structure on tooth surfaces (enamel pellicle). Hsts can be divided into two major groups according to their biological functions: antimicrobial Hsts (e.g. Hst 5/HTN3) and cell-activating Hsts (e.g. Hst 1/HTN1, Hst 2/HTN1 and Hst 3/HTN3) (PubMed:32225006). {ECO:0000269|PubMed:32225006, ECO:0000269|PubMed:3286634}.; FUNCTION: [Histatin-3]: Histatin 3 (Hst 3) is mostly involved in cell migration and wound healing in the oral cavity (PubMed:18650243). Also stimulates cell proliferation after binding to heat shock protein HSC70, which enhances HSC70-CDKN1B complex formation and subsequent ubiquitination during G1/S transition (PubMed:26775844). Also displays antifungal activity against pathogenic yeast Candida albicans, however with less effectiveness than Hst 5 (PubMed:3286634, PubMed:11083804). {ECO:0000269|PubMed:11083804, ECO:0000269|PubMed:18650243, ECO:0000269|PubMed:26775844, ECO:0000269|PubMed:3286634}.; FUNCTION: [His3-(20-43)-peptide]: Histatin 5 (Hst 5), a fragment of Hst 3, is the major histatin exhibiting antifungal and antibacterial activities (PubMed:2372245, PubMed:8945538, PubMed:10066791, PubMed:11083804, PubMed:11179305, PubMed:11717389, PubMed:12939362, PubMed:15485849). It is effective against pathogenic yeast C. albicans, C. neoformans, C. glabrata and S. cerevisiae as well as ESKAPE bacterial pathogens (PubMed:2372245, PubMed:8945538, PubMed:18974864, PubMed:23613860, PubMed:28261570). Secreted Hst 5 mediates a multi-step intracellular mechanism of action against the pathogen. Depending on peptide concentration and pathogen, uptake across the membrane can occur through transporters, direct interaction with plasma membrane and/or receptor-mediated endocytosis (PubMed:18974864, PubMed:20487276, PubMed:28261570). Binds C. albicans cell wall proteins SSA1 and SSA2 and glycans in an energy-independent manner, then is taken up by the cells through fungal polyamine transporters DUR3 and DUR31 in an energy-dependent manner (PubMed:12761219, PubMed:20487276, PubMed:22033918, PubMed:23613860). Internalized Hst5 is then targeted to the energized mitochondrion to induce reactive oxygen species (ROS) formation and subsequent release of intracellular non-lytic ATP which ultimately leads to fungal cell death (PubMed:10066791, PubMed:11717389, PubMed:11083804). In addition, inhibits C. albicans TRK1 potassium-transporter which causes exudation of intracellular K(+), generating an osmotic imbalance leading to delayed membrane lysis and cell death (PubMed:15485849). Also acts as a potent inhibitor of bacterial proteases such as Lys-gingipain and Arg-gingipain (rgpB) from P. gingivalis as well as human metalloproteases MMP2 and MMP9 (PubMed:11179305). The binding of metals such as zinc, copper or nickel with Hst 5 results in the protection of the enamel and antimicrobial activities such as the inhibition of microbial growth by decreasing the metal concentration, the formation of ROS commonly associated with redox-active metals, the induction of membrane disruption mediated by zinc binding (PubMed:19846304, PubMed:28261570, PubMed:28763199, PubMed:32751915). Also involved in coating oral surfaces in the form of a salivary film which reduces colonization by C. albicans on epithelial cell surfaces (PubMed:26379655). Secreted Hst 5 can also internalize mammalian epithelial cells and target the mitochondria although it does not exert cytotoxic effects in these cells (PubMed:32225006). In contrast with Hst 3, not able to promote wound healing in mammalian host cells (PubMed:18650243). {ECO:0000269|PubMed:10066791, ECO:0000269|PubMed:11083804, ECO:0000269|PubMed:11179305, ECO:0000269|PubMed:11717389, ECO:0000269|PubMed:12761219, ECO:0000269|PubMed:12939362, ECO:0000269|PubMed:15485849, ECO:0000269|PubMed:18650243, ECO:0000269|PubMed:18974864, ECO:0000269|PubMed:19846304, ECO:0000269|PubMed:20487276, ECO:0000269|PubMed:22033918, ECO:0000269|PubMed:23613860, ECO:0000269|PubMed:2372245, ECO:0000269|PubMed:26379655, ECO:0000269|PubMed:28261570, ECO:0000269|PubMed:28763199, ECO:0000269|PubMed:32225006, ECO:0000269|PubMed:32751915, ECO:0000269|PubMed:8945538}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - Retained domain in the 5'-partner of fusion protein (protein functional feature from UniProt). |
| Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
| - Retained domain in the 3'-partner of fusion protein (protein functional feature from UniProt). |
| Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
Top |
Kinase-Substrate Information of CSNK1G3_HTN3 |
| Phosphorylation target of the kinase (phosphosite, 03-17-2024) |
| Kinase | Kinase UniProt Acc | Kinase species | Substrate | Substrate UniProt Acc | Substrate phosphorylated residues | Substrate phosphorylated sites (+/-7AA) | Domain |
| CSNK1G3 | Q9Y6M4 | human | SNCA | P37840 | T64 | EktkEQVtNVGGAVV | Synuclein |
| CSNK1G3 | Q9Y6M4 | human | LRP6 | O75581 | T1479 | SSsstKGtyFPAILN | |
| CSNK1G3 | Q9Y6M4 | human | LRP6 | O75581 | S1490 | AILNPPPsPAtERsH | |
| CSNK1G3 | Q9Y6M4 | human | LYN | P07948 | S13 | SKGkDsLsDDGVDLk |
| Biological Network Integration of This Kinase and Substrates (GeneMANIA website) |
| Enriched GO biological processes of the phosphorylation target genes of the kinase |
| Kinase | GOID | GO term | P.adjust |
| CSNK1G3 | ID | Description | 0.00e+00 |
| CSNK1G3 | GO:0006469 | negative regulation of protein kinase activity | 3.26e-04 |
| CSNK1G3 | GO:0033673 | negative regulation of kinase activity | 3.26e-04 |
| CSNK1G3 | GO:0051348 | negative regulation of transferase activity | 3.45e-04 |
| CSNK1G3 | GO:0071900 | regulation of protein serine/threonine kinase activity | 5.13e-04 |
| CSNK1G3 | GO:0001933 | negative regulation of protein phosphorylation | 5.13e-04 |
| CSNK1G3 | GO:0042326 | negative regulation of phosphorylation | 5.32e-04 |
| CSNK1G3 | GO:0045936 | negative regulation of phosphate metabolic process | 6.12e-04 |
| CSNK1G3 | GO:0010563 | negative regulation of phosphorus metabolic process | 6.12e-04 |
| CSNK1G3 | GO:0031400 | negative regulation of protein modification process | 8.49e-04 |
| CSNK1G3 | GO:0043086 | negative regulation of catalytic activity | 1.01e-03 |
| CSNK1G3 | GO:0140029 | exocytic process | 2.95e-03 |
| CSNK1G3 | GO:0051279 | regulation of release of sequestered calcium ion into cytosol | 2.95e-03 |
| CSNK1G3 | GO:0071901 | negative regulation of protein serine/threonine kinase activity | 3.96e-03 |
| CSNK1G3 | GO:0051209 | release of sequestered calcium ion into cytosol | 6.20e-03 |
| CSNK1G3 | GO:0051283 | negative regulation of sequestering of calcium ion | 6.20e-03 |
| CSNK1G3 | GO:0051282 | regulation of sequestering of calcium ion | 6.20e-03 |
| CSNK1G3 | GO:0051208 | sequestering of calcium ion | 6.20e-03 |
| CSNK1G3 | GO:0010950 | positive regulation of endopeptidase activity | 6.97e-03 |
| CSNK1G3 | GO:0010952 | positive regulation of peptidase activity | 7.80e-03 |
| CSNK1G3 | GO:1903169 | regulation of calcium ion transmembrane transport | 7.80e-03 |
| CSNK1G3 | GO:0017157 | regulation of exocytosis | 8.86e-03 |
| CSNK1G3 | GO:0097553 | calcium ion transmembrane import into cytosol | 9.84e-03 |
| CSNK1G3 | GO:0045055 | regulated exocytosis | 1.15e-02 |
| CSNK1G3 | GO:0051651 | maintenance of location in cell | 1.20e-02 |
| CSNK1G3 | GO:0002274 | myeloid leukocyte activation | 1.20e-02 |
| CSNK1G3 | GO:0051924 | regulation of calcium ion transport | 1.25e-02 |
| CSNK1G3 | GO:0006898 | receptor-mediated endocytosis | 1.27e-02 |
| CSNK1G3 | GO:0052548 | regulation of endopeptidase activity | 1.52e-02 |
| CSNK1G3 | GO:0006874 | intracellular calcium ion homeostasis | 1.59e-02 |
| CSNK1G3 | GO:0015850 | organic hydroxy compound transport | 1.59e-02 |
| CSNK1G3 | GO:0052547 | regulation of peptidase activity | 1.59e-02 |
| CSNK1G3 | GO:1904062 | regulation of monoatomic cation transmembrane transport | 1.59e-02 |
| CSNK1G3 | GO:0055074 | calcium ion homeostasis | 1.64e-02 |
| CSNK1G3 | GO:0032496 | response to lipopolysaccharide | 1.64e-02 |
| CSNK1G3 | GO:0006887 | exocytosis | 1.64e-02 |
| CSNK1G3 | GO:0045862 | positive regulation of proteolysis | 1.64e-02 |
| CSNK1G3 | GO:0051235 | maintenance of location | 1.64e-02 |
| CSNK1G3 | GO:0070588 | calcium ion transmembrane transport | 1.64e-02 |
| CSNK1G3 | GO:1990778 | protein localization to cell periphery | 1.64e-02 |
| CSNK1G3 | GO:0002237 | response to molecule of bacterial origin | 1.75e-02 |
| CSNK1G3 | GO:0010959 | regulation of metal ion transport | 1.81e-02 |
| CSNK1G3 | GO:0050727 | regulation of inflammatory response | 1.81e-02 |
| CSNK1G3 | GO:0043434 | response to peptide hormone | 1.81e-02 |
| CSNK1G3 | GO:0009410 | response to xenobiotic stimulus | 1.81e-02 |
| CSNK1G3 | GO:0060368 | regulation of Fc receptor mediated stimulatory signaling pathway | 1.81e-02 |
| CSNK1G3 | GO:0060397 | growth hormone receptor signaling pathway via JAK-STAT | 1.81e-02 |
| CSNK1G3 | GO:1901856 | negative regulation of cellular respiration | 1.81e-02 |
| CSNK1G3 | GO:1905245 | regulation of aspartic-type peptidase activity | 1.81e-02 |
| CSNK1G3 | GO:0006816 | calcium ion transport | 1.81e-02 |
Top |
Related Drugs to CSNK1G3_HTN3 |
| Drugs used for this fusion-positive patient. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Drug | Source | PMID |
| Distribution of the number of studies mentioning CSNK1G3-HTN3 and kinase inhibitors the PubMed Abstract (04-01-2024) |
| Fusion gene - drug pair 1 | Fusion gene - drug pair 2 | PMID | Publication date | DOI | Study title |
Top |
Related Diseases to CSNK1G3_HTN3 |
| Diseases that have this fusion gene. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Disease | Source | PMID |
| Related diseases from the literature mentioned this fusion gene and drug. (PubMed, 04-01-2024) |
| MeSH ID | MeSH term |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Top |
Clinical Trials of the Found Drugs/Small Molecules |
| Statistics of the Clinical Trials of the Found Kinase Inibitors from clinicaltrials.gov (06-17-2024) |
| Clinical Trials from clinicaltrials.gov (06-17-2024) |
| Fusion Gene | Kinase Inhibitor | NCT ID | Study Status | Phases | Disease | # Enrolment | Date |
Copyright 2024-Present -The University of Texas Health Science Center at Houston
Web File Viewing | Emergency Information |Campus Carry|Site Policies |